NAD salvage pathway machinery expression in normal and glaucomatous retina and optic nerve
Abstract Glaucoma is the leading cause of irreversible blindness and is a major health and economic burden. Current treatments do not address the neurodegenerative component of glaucoma. In animal models of glaucoma, the capacity to maintain retinal nicotinamide adenine dinucleotide (NAD) pools decl...
Main Authors: | James R. Tribble, Anna Hagström, Kenza Jusseaume, Emma Lardner, Raymond Ching-Bong Wong, Gustav Stålhammar, Pete A. Williams |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-01-01
|
Series: | Acta Neuropathologica Communications |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40478-023-01513-0 |
Similar Items
-
Nicotinamide and WLDS Act Together to Prevent Neurodegeneration in Glaucoma
by: Simon W. M. John, et al.
Published: (2017-04-01) -
The NAD+ precursor NMN activates dSarm to trigger axon degeneration in Drosophila
by: Arnau Llobet Rosell, et al.
Published: (2022-12-01) -
Nicotinamide treatment robustly protects from inherited mouse glaucoma
by: Pete A. Williams, et al.
Published: (2018-01-01) -
Mesenchymal stem cells for repairing glaucomatous optic nerve
by: Bai-Yu Hu, et al.
Published: (2024-04-01) -
Molecular mechanisms of retinal ganglion cell degeneration in glaucoma and future prospects for cell body and axonal protection
by: Yasunari eMunemasa, et al.
Published: (2013-01-01)